Exact Sciences Corporation (NASDAQ:EXAS) was founded in 1995 and is headquartered in Madison, Wisconsin, with 677 full-time employees. It is a molecular diagnostic company that focuses on non-invasive colorectal cancer screening.
Exact Sciences Corporation (EXAS):
Exact Sciences Corporation is a molecular diagnostic company focused on the development of non-invasive colorectal cancer screening products. Cologuard, developed by Precision Science, is a non-invasive, fecal DNA-based colorectal cancer screening test for detecting pre-cancerous lesions or polyps, and the four stages of colorectal cancer.
The Cologuard test covers: the cells peeled off from the feces from the colon every day, the exclusive and patented method for isolating and studying human DNA; and the detection of blood in feces with protein markers, which is an antibody-based immunochemical stool test.
Precision Science’s stool-based DNA colorectal cancer screening technology also focuses on inflammatory bowel disease (IBD).
In addition, Precision Science Corporation signed a joint research, authorization and procurement agreement with Genzyme Corporation (formerly NASDAQ:GENZ), and developed tests with the Mayo Foundation for medical education and research to detect other gastric cancers, major esophagus and pancreas Dirty cancer, etc.